Present 12-week data from Cohort A of the Phase 1/2 study of DNL310
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 12 Feb 2021
- Delivered
- 12 Feb 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Late-breaker presentation on 12-week data from Cohort A in Phase 1/2 study of DNL310 (ETV:IDS) in Hunter syndrome (MPS II) to be held at WORLD Symposium on February 12th”
What we found
Evidence strength A What the grades mean
Denali Therapeutics presented the 12-week (three-month) data from Cohort A of the DNL310 Phase 1/2 study at the WORLDSymposium on February 12, 2021, as committed.
-
A Denali Therapeutics Inc. 8-K filed 2021-02-12
“The data will be presented later today during a late-breaker session at WORLDSymposium™.” ✓ confirmed on the page
-
A Denali Therapeutics Inc. 8-K filed 2021-02-12
“Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II)” ✓ confirmed on the page
Market reaction: the shares moved -10.1% against the S&P 500 over the three sessions around the disclosure (11 Feb 2021 to 17 Feb 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Deliverable
- DNL310 Phase 1/2 study data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Denali Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-DNLI-021860 · Corrections policy